Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.37Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: -6.43%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
BioRestorative Therapies demonstrated significant progress with their BRTX-100 program, achieving FDA Fast Track designation and clearance for a new clinical trial, positioning the company strongly in the cell-based therapy market. However, financial challenges and a decline in revenue remain concerns.Company Guidance
During the first quarter of 2025, BioRestorative Therapies provided guidance on various financial and operational metrics. The company reported a revenue of approximately $25,000, a decrease from $35,000 in the same period the previous year, but highlighted $150,000 in deferred revenues, indicating timing differences in revenue recognition. The loss from operations rose to $4.8 million from $4.1 million in the first quarter of 2024, and the net loss increased to $5.3 million or $0.64 per share, compared to $2.2 million or $0.33 per share in the prior year, primarily due to a previous gain on warrant exchange. Despite the increased losses, the company maintained a solid financial position with $9.1 million in cash, cash equivalents, and marketable securities, and no outstanding debt. Operationally, the company achieved two significant FDA milestones for its lead candidate, BRTX-100, including a Fast Track designation for its chronic lumbar disc disease program and clearance for a Phase II trial in chronic cervical discogenic pain, while continuing to advance its preclinical ThermoStem program targeting obesity and metabolic disorders.FDA Fast Track Designation for BRTX-100
BioRestorative Therapies received FDA Fast Track designation for their BRTX-100 program targeting chronic lumbar disc disease, facilitating development and expediting review processes.
FDA Clearance for Phase II Clinical Trial in cCDP
The FDA cleared BioRestorative's investigational drug application for a Phase II clinical trial of BRTX-100 in chronic cervical discogenic pain, marking it as the first stem cell-based product candidate to be evaluated in cervical degeneration disc disease.
Strong Financial Position
The company ended the quarter with $9.1 million in cash, cash equivalents, and marketable securities, with no outstanding debt.
Positive Preliminary Data for BRTX-100
Preliminary blinded data shows positive trends in safety and efficacy for BRTX-100 in treating chronic lumbar disc disease, with no serious adverse events reported.
Expansion of ThermoStem IP Portfolio
BioRestorative expanded its intellectual property estate for ThermoStem, covering both U.S. and international markets, to protect its potential treatments for obesity and metabolic disorders.
BRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $1.71 | $1.67 | -2.34% |
Mar 27, 2025 | $1.83 | $1.81 | -1.09% |
Nov 12, 2024 | $1.64 | $1.54 | -6.10% |
Aug 13, 2024 | $1.41 | $1.40 | -0.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioRestorative Therapies (BRTX) report earnings?
BioRestorative Therapies (BRTX) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is BioRestorative Therapies (BRTX) earnings time?
BioRestorative Therapies (BRTX) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BRTX EPS forecast?
BRTX EPS forecast for the fiscal quarter 2025 (Q2) is -0.37.